儿科耐火固体瘤的计量化学疗法:一项回顾性单中心研究
Yukari Sakurai1, Fuminori Iwasaki1, Ayana Hirose1
1Division of Hematology/Oncology, Kanagawa Children's Medical Center.
Journal of pediatric hematology/oncology
|May 1, 2024
概括
计量化学疗法 (MC) 是一种持续的低剂量治疗,显示了对儿科耐火固体瘤的潜力. 虽然没有治愈作用,但MC可以稳定疾病并改善晚期的生存率.
科学领域:
- 在瘤学瘤学.
- 儿科瘤学 儿科瘤学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 计量化学疗法 (MC) 涉及慢性,低剂量的抗癌药物不间断地给予.
- 麦克向瘤血管生成,并促进瘤休眠.
- 它在儿科耐火固体瘤中的有效性需要进一步研究.
研究的目的:
- 评估在患有复发性或耐火性固体瘤的儿童中计量化学疗法的有效性.
主要方法:
- 对18名患有耐火固体瘤的儿科患者进行了回顾性分析,这些患者接受了MC治疗.
- 数据包括MC开始时的疾病状态,整体存活率和无进展存活率.
主要成果:
- 总体生存率在12个月时为61%,在24个月时为34%.
- 在12个月和24个月后,无进展生存率为21%.
- 大约一半的患者经历了瘤稳定和改善的生存率,其中一些患者出现回归或维持缓解.
结论:
- 计量化学疗法证明了作为高级儿科固体瘤的有价值的治疗选择的潜力.
- MC可能会提供生存益处和疾病稳定,即使在疾病进展的患者中也是如此.
- 需要进一步的研究来优化儿童癌症患者的MC协议.
更多相关视频
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)